Chemokines displayed on the luminal surface of blood vessels play pivotal roles in in¯ammatory and homeostatic leukocyte traf®cking in vivo. However, the mechanisms underlying the functional regulation of chemokines on the endothelial cell surface remain ill-de®ned. A promiscuous chemokine receptor, the Duffy antigen receptor for chemokines (DARC), has been implicated in the regulation of chemokine functions. Here we show that DARC is selectively expressed at the mRNA and protein levels in the high endothelial venules (HEV) of unstimulated lymph nodes (LN). To examine the biological signi®cance of DARC expression in HEV, we performed competitive binding experiments with 20 different chemokines. The results showed that DARC selectively bound distinct members of the pro-in¯ammatory chemokines such as CXCL1, CXCL5, CCL2, CCL5 and CCL7, but not lymphoid chemokines such as CCL21, CCL19, CXCL12 and CXCL13 that are normally expressed in HEV. CCL2 bound to DARC failed to induce a signi®cant cytosolic [Ca 2+ ] elevation in CCR2B-expressing cells, whereas the free form of CCL2 induced a distinct [Ca 2+ ] elevation, suggesting that DARC down-regulates activities of pro-in¯ammatory chemokines upon binding. Targeted disruption of the gene encoding DARC did not induce any obvious changes in the cell number or leukocyte subsets in the peripheral and mesenteric LN. Neither did DARC de®ciency signi®cantly affect lymphocyte migration into LN. These results suggest that DARC may be a scavenger for pro-in¯ammatory chemokines, but not a presenting molecule for lymphoid chemokines at HEV and that it is probably functionally dispensable for lymphocyte traf®cking to HEV-bearing lymphoid tissues under physiological conditions.
Introduction
Lymphocyte recirculation plays a vital role in propagating immunological memory and also ensures the immune surveillance of the body (1) . During this process, lymphocytes selectively migrate into lymph nodes (LN) and Peyer's patches by interacting with the specialized high endothelial venules (HEV) (2, 3) . A multistep model has been proposed for the selective interactions between lymphocytes and HEV cells that involves lymphocyte rolling followed by ®rm adhesion and diapedesis, which require rapid activation of lymphocyte integrins (4) . Recent studies established that lymphocyte integrins are activated by chemokines that trigger speci®c Gprotein-coupled receptors expressed on the lymphocyte cell surface (5) . CCL21 (SLC), one of the chemokines expressed in HEV cells, can activate LFA-1 on lymphocytes (5±7) and a mutation in the gene encoding CCL21 (8) results in severely impaired migration of T cells across HEV (6, 7) [chemokine nomenclature used in this study follows guidelines reviewed in (9) ]. A few other chemokines, including CXCL12 (SDF-1) (10), CXCL13 (BLC) (10) , CCL19 (ELC) (11) , CCL2 (MCP-1) (12) and CXCL9 (MIG) (13) , have also been implicated in leukocyte traf®cking across HEV by acting differentially on various leukocyte subsets, thus enabling them to adhere to and migrate across HEV under physiological or pathological conditions. Chemokine expression is tightly controlled temporally and spatially, an indication of the biological importance of these molecules (14, 15) , but the exact mechanism of this regulation is not well understood.
To identify novel molecules expressed speci®cally in HEV, we previously performed gene expression analyses in mouse HEV cells expressing peripheral node addressin (PNAd) (16) or mucosal addressin cell adhesion molecule (MAdCAM)-1 (17) . We found that the PNAd + HEV cells and MAdCAM-1 + HEV cells formed overlapping, but partly different, gene expression patterns (16, 17) . One of the genes commonly found in both types of HEV in mice codes for a promiscuous chemokine receptor, the Duffy antigen receptor for chemokines (DARC) (16, 17) . DARC has also been identi®ed in the lumen of HEV of human tonsils (18) .
DARC carries an antigenic determinant of the Duffy blood group system and is a type I glycoprotein. It spans the plasma membrane 7 times like other chemokine receptors and is the receptor on red blood cells (RBC) for the human malarial parasite Plasmodium vivax (19, 20) . Unlike other heptahelical chemokine receptors, DARC is probably not functionally linked with G-proteins, because it lacks in its cytoplasmic portion the highly conserved DRY motif that is required for Gprotein coupling and, hence, it may not transmit chemokine signals intracellularly (21) . DARC can bind a variety of the CXC and CC chemokines, but not C chemokine (21±26). Two main functions have been postulated for DARC. One is that DARC functions as a sink or scavenger receptor for chemokines (19, 27) . The other is that DARC is involved in the transcytosis of chemokines across endothelial cells and presents them to leukocytes (28±31). Recently, DARC-de®cient mice have been established, but, to our knowledge, the function of DARC in chemokine transport to and presentation at HEV has not been addressed (32, 33) .
In the present study, having con®rmed the expression of DARC in LN HEV, we have examined in detail DARC's repertoire of chemokine binding using both in¯ammatory and lymphoid chemokines, some of which have been implicated in lymphocyte traf®cking across HEV. We have also examined the functional consequence of chemokine binding to DARC in terms of the chemokine's ability to induce intracellular Ca 2+ in¯ux. In addition, we have examined the lymphoid tissues of DARC-de®cient mice to elucidate the physiological signi®cance of DARC in lymphocyte traf®cking.
Methods

Animals and antibodies
All animal experiments were performed under an experimental protocol approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine. Speci®c pathogen-free male C57BL/6 mice were from Japan SLC (Hamamatsu, Japan). DARC-de®cient mice were established and used as described (34) . The MECA-367 mAb (35) was kindly provided by Dr E. C. Butcher (Stanford University, CA). Biotin-conjugated MECA-367 mAb was prepared in our laboratory. All of the following biotin-or FITCconjugated mAb were obtained from BD PharMingen (San Diego, CA): anti-CD3e (145-2C11), anti-B220 (RA3-6B2), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-Gr-1 (RB6-8C5) and antiCD11b (M1/70) mAb.
Chemokines CXCL1 (MGSA), CXCL4 (PF4), CXCL5 (ENA-78), CXCL8 (IL-8), CXCL10 (IP-10), XCL1 (lymphotactin), CCL2, CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3) and CCL8 (MCP-2) of human origin were purchased from PeproTech (Rocky Hill, NJ). Recombinant human CXCL12 was kindly provided by Dr K. Tashiro (Kyoto University, Kyoto, Japan). Recombinant human CCL17 (TARC), CCL18 (PARC), CCL20 (LARC) and CX3CL1 (fractalkine) fused with the secreted form of the placental alkaline phosphatase were kind gifts of Dr O. Yoshie (Kinki University, Osaka, Japan). CCL21 was purchased from Dako (Kyoto, Japan). CXCL13 and CCL19 were from R & D Systems (Minneapolis, MN). 
Cell culture
A mouse endothelial cell line, F-2 (36), was maintained in DMEM (Sigma, St Louis, MO) supplemented with 10% FCS (Gibco/BRL, Grand Island, NY), 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 1% (v/v) 100 Q non-essential amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin and 50 mM 2-mercaptoethanol. A murine pre-B cell line, L1.2, that expresses human CCR2B (L1.2/CCR2B) (37), was kindly provided by Dr O. Yoshie. These cells were cultured in RPMI 1640 (Sigma) containing the same supplements as above and 0.8 mg/ml Geneticin (G418; Sigma).
Establishment of stable transfectants expressing murine DARC
The expression plasmid pcDNA3.1 (Invitrogen, Groningen, The Netherlands) containing a full-length cDNA insert encoding the murine DARC (pcDNA3.1/DARC) was a gift of Dr A. S. Pogo (New York Blood Center) (25) . Transfection of F-2 cells with the cDNA was performed using Lipofectamine (Gibco/ BRL) according to the manufacturer's instructions. The transfected cells were selected with G418 (1.0 mg/ml). A murine DARC + transformant from a single colony was obtained and designated as F-2/DARC.
In situ hybridization
A digoxigenin-labeled single-strand RNA probe for DARC was prepared as follows. The expression plasmid pcDNA3.1/ DARC was digested with KpnI and HindIII, and the resultant cDNA fragment, containing the coding region of DARC (0.7 kb), was inserted into the KpnI±HindIII-digested pBluescript SK vector (Stratagene, La Jolla, CA). Digoxigenin-labeled antisense and sense RNA probes were prepared with T3 polymerase (Stratagene) and T7 polymerase (Stratagene) respectively using the DIG RNA Labeling Mix (Roche, Mannheim, Germany). In situ hybridization with mouse LN sections was performed as described (16) .
Generation of rabbit polyclonal antibody (pAb) against murine DARC
A pAb was raised against the C-terminal intracellular region of mouse DARC by s.c. immunization of rabbits with a keyhole limpet hemocyanin-conjugated synthetic peptide, LPTRQAS-QMDALAGK, which corresponds to amino acids 319±333 of the mouse DARC. The pAb was puri®ed from immunized rabbit serum using a synthetic peptide-conjugated Sepharose column.
Immunohistochemistry
Frozen sections (8 mm) of LN were ®xed in acetone and then in 4% paraformaldehyde in a 1% calcium chloride solution. After blocking, sections were incubated with biotinylated MECA-367 mAb or biotinylated anti-DARC pAb. The sections were washed in PBS and then incubated with the alkaline phosphatase-conjugated ABC reagent (Vector, Burlingame, CA). After gentle ®xation in 1% glutaraldehyde in PBS, the sections were stained using Vector Red (Vector). For the analysis of DARC-de®cient mice, ®xed cryosections were incubated with biotin-conjugated mAb against cell-surface markers as indicated. After washing, the sections were stained with the horseradish peroxidase-conjugated ABC reagent (Vector) and Metal Enhanced DAB (Pierce, Rockford, IL), followed by counter-staining with hematoxylin.
Chemokine-binding analysis
For the competitive chemokine-binding analysis, the F-2 and F-2/DARC cells (4 Q 10 5 cells/100 ml) were incubated at 4°C for 1 h with 0.2 nM 125 I-labeled CXCL1 in the presence or absence of excess amounts of unlabeled chemokines as competitors (20 nM). The cell suspension was then layered over 200 ml of a mixture of 80% dibutyl phthalate/20% olive oil (Sigma). The cell-associated radiolabeled CXCL1 was separated from unbound radioactivity by centrifugation and quanti®ed in a g-counter. All reactions were performed in triplicate and all experiments were performed at least twice.
Calcium mobilization assay
Calcium mobilization was measured by loading L1.2/ CCR2B cells (1 Q 10 6 /ml) with 2 mM Indo-1 acetoxymethylester (Sigma) at 37°C for 30 min in RPMI medium containing 1% FCS. The cells were analyzed by an Epics Elite¯ow cytometer (Beckman Coulter, Miami, FL) using UV excitation with uorescence emission collected as a ratio of 406:525 nm, as described previously (38) . The mean ratio plotted against time was acquired using Multitime software for analysis of kinetic ow cytometry data (Phoenix Flow Systems, San Diego, CA). The RBC-associated CCL2 was prepared as follows: mouse RBC (2 Q 10 9 cells) in 0.5 ml of PBS containing 1% FCS (PBS/ FCS) were incubated with 10 nM CCL2 at 37°C for 20 min. Unbound CCL2 was removed by two 250-ml washes with PBS/ FCS. The RBC were then mixed with Indo-1-loaded L1.2/ CCR2B cells (at an indicator cell:RBC ratio of 1:200) in a total volume of 0.5 ml and the mixture was immediately injected into the¯ow cytometer. The RBC were electronically gated using a combination of the light scatter and Indo-1¯uorescence. To determine the amount of CCL2 bound to the RBC, the binding of 125 I-labeled CCL2 to mouse RBC was measured as follows. Freshly isolated mouse RBC (2 Q 10 9 cells) (27) in 0.5 ml of PBS/FCS were incubated with 10 nM 125 I-labeled CCL2 at 37°C for 20 min. Unbound CCL2 was removed by two 250-ml washes with PBS/FCS and the radioactivity in the cell pellet was quanti®ed in a g-counter. To monitor release of bound CCL2 from RBC, the RBC were resuspended in 0.5 ml of PBS/ FCS and incubated at room temperature for up to 60 min. Measurement of RBC-associated radioactivity showed no signi®cant release of bound CCL2 from RBC (data not shown).
Cell counts and¯ow cytometric analysis
Single-cell suspensions from the spleen and LN from wild-type and DARC-de®cient mice were prepared by gentle mincing. Cell numbers were counted manually using a hemocytometer. For¯ow cytometry, cells (1 Q 10 6 ) were incubated with FITCconjugated mAb (5 mg/ml) against cell-surface markers as indicated at 4°C for 30 min in 50 ml of PBS containing 1% BSA and 0.05% NaN 3 . The cells were washed twice and analyzed on an Epics XL¯ow cytometer using System II software (Beckman Coulter). 
In vivo migration assay
Total spleen cells were prepared from green¯uorescent protein (GFP)-transgenic mice of the C57BL/6 background (39). The GFP + spleen cells (1 Q 10 7 cells) were injected i.v. into age-and sex-matched wild-type mice or DARC-de®cient mice. The mice were sacri®ced 6 h after injection, and the spleen, mesenteric LN, peripheral LN and Peyer's patches were harvested. The numbers of T cells, B cells and Mac-1 + cells that had migrated into these tissues were determined bȳ ow cytometry using an Epics-XL and FACScan (BD Biosciences, San Jose, CA).
Results
DARC is expressed in the HEV of unchallenged, quiescent LN
It has been reported that DARC is expressed in the postcapillary venules of various tissues (40, 41) , including HEV of the palatine tonsils in humans (18) . However, because the post-capillary venules are the sites where in¯ammatory cells often extravasate under pathological conditions and because tonsils are exposed to various types of immunological assaults due to their strategic location, it remained unclear whether the DARC expressed at these locations is induced by exogenous stimulation or is constitutively expressed.
An mRNA hybridization analysis in situ showed that an antisense probe to DARC hybridized preferentially to HEV cells of mesenteric LN from unchallenged mice (Fig. 1A) , as did the antisense probe to an HEV marker, GlyCAM-1 (Fig. 1C) . In contrast, no signi®cant signal was observed with the DARC sense probe (Fig. 1B) . Similar results were observed in inguinal LN of unchallenged mice (Fig. 1D) . Immunouorescence staining with a pAb to DARC con®rmed the expression of the DARC protein in MAdCAM-1 + HEV cells, which appeared to be preferentially distributed to the basolateral and apical surface of HEV cells (Fig. 2) . A much weaker immunoreactive signal was also observed in a small proportion of¯at non-HEV-type endothelial cells. The anti-DARC pAb failed to react with any cell components in LN sections of DARC-de®cient mice, verifying the speci®city of this antibody (data not shown). These results demonstrate that DARC is preferentially and constitutively expressed at the mRNA and protein levels in HEV cells of unchallenged, quiescent LN of speci®c pathogen-free mice, and not induced by antigenic stimulus.
DARC binds pro-in¯ammatory, but not lymphoid, chemokines.
Although previous studies showed that DARC binds a variety of in¯ammatory chemokines belonging to the CXC and CC classes (21±26), whether DARC can bind members of the lymphoid chemokines has not been determined to our knowledge. To examine the binding speci®city of DARC to various chemokines by a competitive binding inhibition analysis, we established an F-2 endothelial cell line that stably expressed DARC (F-2/DARC). To assess the binding speci®city of DARC, 20 different chemokines were used as cold competitors (at a ®nal concentration of 20 nM) against 0.2 nM of 125 I-labeled CXCL1. As shown in Fig. 3 , the binding of 125 I-labeled CXCL1 to F-2/DARC was strongly inhibited by the addition of excess amounts of in¯ammatory chemokines, including CXCL1, CCL7, CXCL5, CCL5 and CCL2, and moderately inhibited by CCL17 and CCL8. No signi®cant displacement of 125 Ilabeled CXCL1 binding was observed with chemokines, including CXCL10, CCL3, CCL4 and CXCL8. These results are consistent with the previous observations showing that DARC binds multiple, but restricted, members of the in¯am-matory chemokines (21±26). In contrast, the binding of 125 I- labeled CXCL1 was uniformly unaffected by the addition of any of the lymphoid chemokines examined, including CCL21, CCL19, CXCL12 and CXCL13, indicating that DARC does not bind these chemokines. Furthermore, the CXCL1 binding was not affected by CX3CL1, CCL20, CCL18 or XCL1. Lack of CCL21 binding to F-2/DARC was also con®rmed by¯ow cytometric analysis using pAb speci®c to CCL21 (data not shown). These results clearly indicate that, although DARC binds the ELR-CXC and CC classes of chemokines in a seemingly promiscuous manner, it actually binds only a certain member of the pro-in¯ammatory chemokines and fails to bind the lymphoid chemokines.
CCL2 bound to DARC fails to induce Ca 2+ signals in CCR2B-expressing cells
Because of its capacity to bind multiple chemokines, DARC has been implicated in the modulation of chemokines' biological activities. To address this issue, we examined the ability of CCL2 bound to DARC to induce a Ca 2+ in¯ux in the L1.2/CCR2B cells. Free CCL2 was used as a control and found to induce a prominent Ca 2+ response in the L1.2/CCR2B cells in a dose-dependent manner with a threshold concentration of 0.6 nM (Fig. 4A) . Next, CCL2 (10 nM) was added to RBC that express DARC abundantly (19, 20) to prepare cells with CCL2 bound to the cell-surface DARC (CCL2-loaded RBC). Determination of the amount of CCL2 bound to RBC using 125 I-labeled CCL2 indicated that~60% of the CCL2 added bound to the RBC (Fig. 4B) . No signi®cant release of bound CCL2 from RBC was observed under the conditions used in this study (data not shown). In a separate series of experiments using RBC from DARC-de®cient mice, we con®rmed that essentially all the CCL2 binding to RBC was bound to DARC (data not shown). The CCL2-loaded RBC were then mixed with the L1.2/CCR2B cells at an indicator cell:RBC ratio of 1:200, which would provide a CCL2 concentration of~6 nM (~10-fold higher than the threshold concentration) in the test sample. The measurement of Ca 2+ in¯ux by¯ow cytometry showed that the CCL2 bound to DARC did not induce any signi®cant Ca 2+ in¯ux in the L1.2/CCR2B cells (a in Fig. 4C ).
Enhancing the physical contact between the DARC-bound RBC and the L1.2/CCR2B cells with strong centrifugal force prior to the measurement of Ca 2+ in¯ux did not result in the induction of a signi®cant Ca 2+ in¯ux in the receptor-bearing cells (data not shown). In contrast, free CCL2 (6 nM) added to the same cells elicited a rapid Ca 2+ in¯ux (b in Fig. 4C) , showing that DARC did not present CCL2 effectively to the L1.2/CCR2B cells, at least under the experimental conditions we used. Admittedly, these experiments were performed under rather arti®cial conditions and also did not directly address the function of the DARC expressed on HEV cells. The results are, however, compatible with the hypothesis that the membrane-bound DARC does not present chemokines effectively, but rather scavenges them (19, 27) .
DARC-de®cient mice show no apparent abnormalities in their LN
To further investigate the physiological signi®cance of DARC in lymphocyte traf®cking, we established DARC-de®cient mice by targeted gene disruption. The secondary lymphoid tissues of DARC-de®cient mice were then examined according to cell number, composition of leukocyte subsets and tissue architecture. In the mesenteric and peripheral LN of DARCde®cient mice, there were no signi®cant differences in the overall cell number and composition of leukocyte subsets including T cells, B cells, macrophages and granulocytes, as compared with the age-and sex-matched wild-type mice (Fig. 5A, upper and lower panels) . The compartmentalization of T and B cells was also apparently normal in the DARCde®cient mice (Fig. 5B) . In addition, Gr-1 + cells, CD11b + cells and F4/80 + cells were also distributed normally in the DARCde®cient mice (data not shown). The DARC de®ciency also did not signi®cantly affect migration of T cells, B cells and Mac-1 + cells into the spleen, mesenteric and peripheral LN, and Peyer's patches as evaluated in the short-term in vivo migration assay (data not shown). The only noticeable change was observed in the spleen of the DARC-de®cient mice. In 6-to 9-week-old DARC-de®cient mice, there was~1.7-fold increase in the total cell number (Fig. 6A) , but there was no signi®cant (Fig. 6B) . In older mice, there was no overt splenomegaly. Collectively, the DARC-de®cient mice showed no apparent abnormalities in their LN, with only a moderate and transient splenomegaly of unknown etiology in young mice, indicating that DARC is dispensable, at least for lymphocyte entry and egress from LN under physiological conditions.
Discussion
Here we con®rm and extend our previous observation by showing that DARC is constitutively expressed in the HEV of unchallenged LN (16, 17) and that it binds selected in¯amma-tory, but not lymphoid, chemokines. In agreement with the binding studies using mouse RBC (24±26), the competitive inhibition of chemokine binding to mouse DARC expressed on endothelial cells indicated that DARC binds only restricted members of the in¯ammatory chemokines including CXCL1, CCL7, CXCL5, CCL5 and CCL2. Interestingly, DARC bound none of the lymphoid chemokines tested, including CCL21, CCL19, CXCL13, CXCL12, CX3CL1, CCL20 and CCL18. Lack of CCL21 binding to DARC expressed on endothelial cells was also con®rmed by¯ow cytometric analysis by the use of speci®c pAb to CCL21 (data not shown). DARC's uniform inability to bind lymphoid chemokines, which was also con®rmed using mouse RBC (data not shown), is interesting, since one of the postulated functions of DARC is the docking of chemokines to concentrate them on the surface of endothelial cells for presentation to speci®c receptors on immune cells (28±31). However, most of the chemokines detectable in HEV, such as CCL21 (6,7), CCL19 (11), CXCL12 (10) and CXCL13 (10), failed to bind DARC, clearly indicating that these chemokines are localized to the HEV independent of DARC. Although CXCL9 has recently been shown to be expressed in HEV in in¯amed LN (13), we have not examined its ability to bind DARC.
The CCL2 bound to RBC failed to induce Ca 2+ in¯ux in the CCR2B-expressing cells (Fig. 4) . The failure to respond to the RBC-associated CCL2 was not due to damage to the CCR2B-expressing cells or a loss of sensitivity of these cells to CCL2, since the same cells showed a distinct increase in intracellular free calcium when free CCL2 was added to the mixture. Virtually all CCL2 binding to RBC was mediated by DARC, because no signi®cant binding of CCL2 was observed in DARC-de®cient RBC (data not shown). Therefore, these results indicate that CCL2 became inaccessible to the receptor-bearing cells upon binding to DARC, which is in accordance with the report by Darbonne et al. (27) in which CXCL8 absorbed to RBC was also shown to be incapable of stimulating neutrophils. While Darbonne et al. (27) used an indicator cell (neutrophil):RBC ratio of 1:100, we used a higher indicator cell (CCR2B transfectant):RBC ratio of 1:200, so that a higher chemokine concentration would be obtained in the assay. With this ratio,~6 nM of CCL2 was present as a DARCassociated form (Fig. 4B) ; 1 nM CCL2 was suf®cient to induce an increase in Ca 2+ in¯ux in the L1.2/CCR2B cells in this assay (Fig. 4A) . However, the CCL2 associated with DARC failed to induce any Ca 2+ in¯ux in the L1.2/CCR2B cells (Fig. 4C) . When CXCL1 was used, the RBC-associated CXCL1 also failed to induce a signi®cant Ca 2+ in¯ux in its cognate receptor-bearing cells (data not shown).
At present, several possibilities could account for the inability of DARC-bound chemokines to stimulate the receptor-bearing cells. First, DARC may physically mask the chemokines' binding site for their cognate receptors. Supporting this hypothesis, DARC has been shown to occupy CXCL1's binding sites for its cognate receptor (CXCR2) at least partially (42) . Second, a conformational change may be induced in the chemokines upon binding to DARC that prevents them from binding their cognate receptors. This hypothesis is, however, currently dif®cult to verify in the absence of structural data from chemokines complexed with DARC. Finally, while the DARC-bound chemokines may still have the capacity to bind to the receptors, they could be physically inaccessible to the receptor-bearing cells under the experimental conditions used. Although we cannot as yet formally exclude this possibility, we do not think it very likely, since basically the same result was obtained when the chemokine-associated RBC were forced to make contact with the receptor-bearing cells by strong centrifugal force (data not shown). In addition, it may be argued that these results were obtained with cultured endothelial cells and not with HEV. However, the observed ability of DARC to bind restricted members of the in¯ammatory chemokines is in accordance with previous observations by others (21±26). We therefore speculate that DARC expressed in HEV also binds selected members of in¯ammatory chemokines and probably limits their access to immune cells, helping to ensure the highly selective transendothelial migration of lymphocytes through HEV.
To address the role of DARC in physiological lymphocyte traf®cking across HEV, we established DARC-null mice by targeted disruption of the DARC gene and examined their lymphoid tissues. Consistent with previous reports (32,33), we observed no signi®cant alterations in the composition of leukocyte subsets and the histological architecture of LN in the DARC-de®cient mice (Fig. 5) . In addition, we found that lymphocyte migration into LN was not compromised in DARCde®cient mice signi®cantly (data not shown). These ®ndings suggest that lymphocyte traf®cking through HEV is unaffected by the deletion of DARC in HEV and that DARC is functionally dispensable in this cellular event. In this regard, it is of note that HEV in unchallenged LN express a pro-in¯ammatory chemokine, CXCL1 (KC), at the mRNA and protein levels (Y. Ebisuno and T. Tanaka, unpublished observation). Given that HEV do not allow traf®cking of neutrophils and monocytes into the LN under physiological conditions, the biological activity of CXCL1 might be masked by chemokine-binding molecules such as DARC in situ, while molecules other than DARC such as proteoglycans (43, 44) and/or various sialomucins (45) could also be involved in the sequestration of in¯ammatory chemokines at the HEV cell surface.
The function of DARC in the spleen is unclear. In 6-to 9-week-old DARC-de®cient mice, the spleen showed a signi®-cant increase in wet weight and cell number (Fig. 6A) , although there was no remarkable alteration in the composition of leukocyte subsets or the histological architecture (Fig. 6B) . In older mice, no splenomegaly was observed. DARC is expressed in the endothelial cells lining the sinusoids in the splenic red pulp (19) . Although the study of DARC-null mice by others indicates that DARC regulates leukocyte traf®cking during in¯ammation (32,33), we have found no evidence that suggests the involvement of DARC in cellular traf®cking in the unstimulated spleen in the present study.
Previous studies by the use of DARC-de®cient mice yielded con¯icting results regarding the DARC's role in in¯ammatory responses in vivo; Dawson et al. (33) reported signi®cantly increased leukocyte in®ltration into the lung and liver after lipopolysaccharide challenge in DARC-de®cient mice, which is in favor of the hypothesis that the DARC functions as a chemokine scavenger. In contrast, Luo et al. (32) reported apparently contradictory results showing that leukocyte recruitment into the lung was decreased in mice lacking DARC. Although our in vitro and in vivo results appear concordant with the notion of DARC being a chemokine scavenger, DARC's role under pathological conditions remains to be fully investigated. Clearly further studies are needed to de®ne the role of DARC in the regulation of chemokine activities and leukocyte traf®cking in vivo more precisely.
Collectively, the results from our study demonstrate that DARC binds only a subset of the in¯ammatory chemokines and fails to bind the lymphoid chemokines that have been implicated in the regulation of lymphocyte traf®cking into secondary lymphoid tissues. Upon binding certain in¯amma-tory chemokines, DARC may limit their access to the cells in the vicinity, thus negatively regulating the chemokines' activities on the endothelial cells. However, under physiological conditions, the DARC expressed in HEV is apparently redundant in terms of lymphocyte traf®cking into the LN.
